Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorNuvalent Inc.
About this trial
The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.
Eligibility criteria
Qualifiers
Age ≥18 years.
Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumor with documented ROS1 rearrangement.
Previously received at least 1 prior ROS1 TKI, with no comparable or satisfactory alternative treatment options, in the opinion of the treating physician.
Enrollment in a clinical trial of zidesamtinib is not possible.
Disqualifiers
Prior receipt of zidesamtinib.
Previous surgery, chemotherapy, radiotherapy or other anti-cancer therapy or participation in other studies within timeframe indicated in the protocol.
Ongoing anti-cancer therapy.
Eligible for ongoing clinical trial with zidesamtinib
Trial design
Treatments tested in this trial
- NVL-520
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov